Lipigon Q2 2023: A pivotal quarter - Redeye

Since our Q1 update, Lipigon signed a deal with Leaderna for Greater China and reported a favourable safety profile and target engagement in the phase I study of Lipisense. A phase IIa study is under preparation and expected to start this year. The finances are in good shape thanks to the upfront payment of USD1.5m and the net proceeds from the rights issue of around SEK23m.

Länk till analysen i sin helhet: https://www.redeye.se/research/939877/lipigon-q2-2023-a-pivotal-quarter?utm_source=finwire&utm_medium=RSS